Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428 | Suspended

• 3 other identifiers: CHA-IRB-1179/03/213R33AT010125R01CA229355
• Study Type: observational
• Target: 817
• Locations: 1 country
• Sites: 1

Brief Summary

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Conditions

Opioid-use Disorder; Acceptability of Health Care; Opioid-Related Disorders

Keywords

Opioid Use Disorder; Substance Use Disorders; Buprenorphine; Suboxone; Cannabis; Cigarettes; E-Cigarettes; Benzodiazepines; Healthcare; COVID-19; Telemedicine; Office-Based Opioid Treatment; Facebook; Social Media; Nicotine; Recovery

Outcome Measures

Primary Outcomes (5)

• Patient's Experiences with Office-Based Opioid Treatment

  This is an eight-item scale that measures the degree to which participants report being able to access buprenorphine treatment-related appointments and medications before and during the COVID-19 pandemic. Participants will be asked to rate each of the eight questions on a 7-point Likert scale from 1 = "extremely easy" to 7= "extremely difficult."

  Day 1

• Reasons for Abstaining from Opioids Questionnaire

  This 17-item scale will measure participant ratings of the importance of 17 factors that motivate abstinence from illicit drug use during office-based opioid treatment. Participants will be asked to rate each of these 17 items on a scale from 0 = "not at all important" to 4 = "extremely important."

  Day 1

• Patients' Attitudes Toward the Use of Cannabis During Office-Based Opioid Treatment

  Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which they feel cannabis use is acceptable during office-based opioid treatment (OBOT), they believe that their prescribers' feel cannabis use is acceptable during OBOT, and they feel comfortable discussing cannabis use with their buprenorphine prescribers.

  Day 1

• Patients' Attitudes Toward the Use of Cigarettes/E-Cigarettes During Office-Based Opioid Treatment

  Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which patients should be encouraged to quit smoking cigarettes and e-cigarette during office-based opioid treatment (OBOT) and the degree to which they feel smoking helps manage cravings during OBOT.

  Day 1

• Patients' Attitudes Toward and Experiences with the Use of Benzodiazepines during Office-Based Opioid Treatment

  Participants will rate three items on a scale of 1 = "completely disagree" to 7 = "completely agree." Specifically, participants will rate the degree to which benzodiazepine use is acceptable during office-based opioid treatment (OBOT), they feel OBOT providers find benzodiazepine use by their patients acceptable, and they feel comfortable openly discussing their benzodiazepine use with their buprenorphine prescriber.

  Day 1

Study Arms (5)

Survey 1

Survey investigating patients' experiences with buprenorphine treatment for Opioid Use Disorder before and during the COVID-19 pandemic

Survey 2

Survey investigating the factors that motivate patients to abstain from opioid drug use during buprenorphine treatment for Opioid Use Disorder

Survey 3

Survey investigating patients' attitudes towards and experiences with cannabis use during buprenorphine treatment for Opioid Use Disorder.

Survey 4

Survey investigating patients' attitudes towards and experiences with cigarettes and e-cigarettes use during buprenorphine treatment for Opioid Use Disorder.

Survey 5

Survey investigating patients' attitudes towards and experiences with benzodiazepine use during buprenorphine treatment for Opioid Use Disorder.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The subject population consists of adults aged 18+ who live in Massachusetts and are currently prescribed buprenorphine by a healthcare provider to treat OUD. Those under the age of 18 will be screened out of the investigation during the consent process. In addition, because many of the survey questions used in this investigation are based on established survey instruments that were created in the English language and validated among English-speaking participants, we will limit the subject population or this study to English-speaking adults.

You may qualify if:

• Participants must be 18 years of age or older.
• Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
• Participants must have a past or present opioid use disorder.
• Participants must currently reside in the state of Massachusetts.
• Participants must be able to comprehend the English language.

You may not qualify if:

• Unable to complete an online survey.
• Unable to complete a verification step that ensures bots are not used to complete survey.
• Complete a survey with no variation suggesting they did not read the survey.

Sponsors & Collaborators

• Cambridge Health Alliance: lead
• National Cancer Institute (NCI): collaborator
• National Center for Complementary and Integrative Health (NCCIH): collaborator

Study Sites (1)

CHA Center for Mindfulness and Compassion

Cambridge, Massachusetts, 02141, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders; Patient Acceptance of Health Care; Substance-Related Disorders; Marijuana Abuse; Vaping; COVID-19

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Treatment Adherence and Compliance; Health Behavior; Behavior; Smoking; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Zev Schuman-Olivier, MD

  Cambridge Health Alliance

  PRINCIPAL INVESTIGATOR

• Joseph Rosansky

  Cambridge Health Alliance

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 21, 2021
• First Posted: November 16, 2021
• Study Start: November 20, 2021
• Primary Completion: March 20, 2025
• Study Completion (Estimated): March 20, 2027
• Last Updated: July 11, 2025

Record last verified: 2025-06

Locations

US (1)